Skip to content
Search

Latest Stories

Djokovic case 'really not good' for sport, says Murray

ANDY MURRAY expressed concern for Novak Djokovic on Sunday (9), saying that other players were shocked and the circumstances surrounding the world number one's barred entry into Australia was "really not good for tennis".

The Serb was hoping to win a record 21st Grand Slam at the Australian Open later this month, but instead of training he has been confined to a room in a hotel in Melbourne used to accommodate asylum seekers.


Djokovic, 34, won a victory on Monday (10) over the Australian government, overturning the cancellation of the tennis star’s visa on Covid-19 health grounds, and ending his detention.

"I think everyone is shocked by it, to be honest," former world number one Murray was quoted as saying by local media in Australia.

"I hope that Novak is OK. I know him well, and I've always had a good relationship with him and I hope that he's OK."

"It's really not good for tennis at all, and I don't think it's good for anyone involved."

Djokovic, who has publicly criticised mandatory vaccines, has consistently refused to disclose his inoculation status and said he had been granted a medical exemption to compete in Australia.

Australian Open chief Craig Tiley blamed conflicting and quickly changing directives in a "challenging environment" for the confusion that resulted in Djokovic being refused entry to the country on a medical exemption.

"(I need to) wait and hear exactly what the situation is before commenting on it further, because again I don't think it's fair because some of it is speculation," Murray said.

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less